GLP-1 medications and dizziness: a 500,000-person study finds real risk

TL;DR

A retrospective cohort study of nearly 500,000 GLP-1 users published in Biomedicines found semaglutide increased vestibular disorder risk 4-5x compared to matched controls, and tirzepatide increased it 3-4.5x. Benign positional vertigo was the most common condition diagnosed, occurring in 67% of cases. This is a real, underreported side effect that most patients and prescribers are not monitoring for.

You know about nausea on Ozempic. You have probably heard about hair loss, fatigue, and the dreaded "Ozempic face." But dizziness and vertigo? That one rarely comes up in the prescribing conversation - and a new large-scale study suggests it should.

Researchers used the TriNetX research network - one of the largest real-world clinical databases in the world - to examine vestibular disorder rates in GLP-1 users. The numbers they found were striking enough that the lead author's team submitted the analysis to Biomedicines in early 2025.

What vestibular disorders actually are

The vestibular system is the body's balance and spatial orientation system, centred in the inner ear. When it malfunctions, you get symptoms ranging from mild dizziness to debilitating spinning vertigo, tinnitus (ringing in the ears), nausea, and difficulty with balance and coordination. The most common vestibular disorders include:

• Benign paroxysmal positional vertigo (BPPV) - brief spinning episodes triggered by head movement
• Ménière's disease - recurring attacks of vertigo with hearing changes and tinnitus
• Peripheral vestibular neuritis - inflammation of the balance nerve
• Central vestibular disorders - balance problems originating in the brain

These are not trivial conditions. BPPV can cause falls. Ménière's disease significantly affects quality of life. And dizziness is one of the leading causes of emergency room visits in adults over 50 - the demographic that overlaps heavily with GLP-1 medication users.

The study: nearly 500,000 patients compared

The research team, led by Eman Toraih at Tulane University, drew data from January 2018 to October 2024. They identified two cohorts: 419,497 semaglutide users and 77,259 tirzepatide users, each matched 1:1 with controls on age, sex, race, and relevant comorbidities using propensity score matching.

The comparison groups had similar baseline characteristics: mean age around 52-55 years, majority female (58-61%), predominantly white. Common comorbidities included hypertension (43-47%), diabetes (36-44%), and obesity (38-41%).

Semaglutide results

Vestibular disorder incidence in the semaglutide group versus matched controls:

• 6 months: 0.12% vs 0.03% (hazard ratio: 4.02)
• 1 year: 0.22% vs 0.06% (hazard ratio: 4.26)
• 3 years: 0.41% vs 0.16% (hazard ratio: 4.95)

The risk grew over time rather than staying constant. At three years on semaglutide, users were nearly five times more likely to have a diagnosed vestibular disorder than matched controls who were not on GLP-1 medications.

Tirzepatide results

Vestibular disorder incidence in the tirzepatide group versus matched controls:

• 6 months: 0.10% vs 0.04% (hazard ratio: 3.19)
• 1 year: 0.15% vs 0.06% (hazard ratio: 4.26 - matching semaglutide at this timepoint)
• 3 years: 0.19% vs 0.15% (hazard ratio: 4.55)

Importantly, semaglutide carried a higher risk than tirzepatide. The risk ratio between the two drugs ranged from 1.53 at six months to 2.04 at three years (p < 0.001). In other words, semaglutide users were up to twice as likely as tirzepatide users to develop vestibular disorders over the same period.

What was actually being diagnosed

Among confirmed vestibular disorder cases, the breakdown was:

• Benign paroxysmal positional vertigo (BPPV): 67.3% of all cases (69.8% in semaglutide, 58.4% in tirzepatide users)
• Ménière's disease: 11.1%
• Other peripheral vertigo: 12.9%
• Central vestibular disorders: more common with tirzepatide (8.6%) than semaglutide (4.2%)

BPPV dominating the picture makes biological sense: it can be triggered by rapid weight loss and postural changes, both of which are common in GLP-1 users. However, the fact that absolute incidence is still rising at three years argues against rapid weight loss alone as the explanation.

Why might GLP-1 medications affect the inner ear?

The researchers proposed five potential mechanisms. None are definitively proven, but all are biologically plausible:

• Central vestibular modulation - GLP-1 receptors exist in the brainstem, including areas involved in balance processing
• Inner ear fluid disruption - vasodilation from GLP-1 receptor activation may alter endolymph fluid pressure in the inner ear
• Mitochondrial stress in hair cells - the hair cells of the inner ear are metabolically demanding; GLP-1-induced metabolic changes may stress these cells
• Autonomic dysregulation - GLP-1 medications affect the autonomic nervous system, which also regulates inner ear blood flow
• Rapid weight loss effects - dehydration, electrolyte shifts, and postural hypotension during weight loss can independently trigger dizziness and vestibular symptoms

The weight loss mechanism is particularly relevant for GLP-1 users. Rapid weight loss causes fluid shifts and electrolyte changes - specifically in sodium, potassium, and magnesium - that are well-established triggers for dizziness and balance problems. This is a point where nutrition directly intersects with this side effect.

The magnesium and electrolyte connection

Magnesium deficiency - one of the most consistently documented nutrient gaps in GLP-1 users due to reduced food intake - is independently associated with inner ear dysfunction and tinnitus. Several clinical cases in the literature describe tinnitus and vestibular symptoms resolving with magnesium repletion. While this does not prove that magnesium supplementation prevents GLP-1-related vestibular problems, it raises the question of whether the nutrient gaps that GLP-1 medications create may be contributing to the vestibular risk this study quantified. GLP-1 Shield includes magnesium specifically because of its documented deficiency risk in this population.

What to watch for and when to see a doctor

Most dizziness in GLP-1 users is mild and transient, related to postural hypotension (blood pressure drops when standing quickly) or dehydration. But if you experience any of the following, it is worth a conversation with your prescriber:

• Sudden, severe spinning vertigo (room spinning) rather than lightheadedness
• Dizziness triggered specifically by head position changes - a hallmark of BPPV
• Tinnitus (ringing or buzzing in the ears) that has started or worsened since starting GLP-1 medications
• Hearing changes, especially in one ear
• Balance problems that affect your ability to walk safely

BPPV is very treatable - a physical manoeuvre called the Epley manoeuvre repositions the ear crystals that cause it and resolves symptoms in most people within a session or two. The key is getting the right diagnosis first.

Frequently asked questions

Can Ozempic or Wegovy cause dizziness and vertigo?

Yes. A large real-world study of 419,497 semaglutide users found they were 4-5x more likely to develop vestibular disorders (dizziness, vertigo, tinnitus) than matched controls not on GLP-1 medications. The most common condition diagnosed was benign paroxysmal positional vertigo. The risk was real but the absolute numbers were still small - around 0.4% of users over 3 years versus 0.16% in controls.

Is tirzepatide (Mounjaro, Zepbound) safer than semaglutide for dizziness?

Based on this study, tirzepatide appears to carry somewhat lower vestibular disorder risk than semaglutide. At 3 years, semaglutide users were roughly twice as likely as tirzepatide users to have a vestibular disorder diagnosis. The reason for this difference is not yet clear - it may relate to the different receptor profiles or the GIP component of tirzepatide affecting the vestibular pathway differently.

What can I do to reduce dizziness risk on GLP-1 medications?

Staying well hydrated is the most practical step - dehydration is a common and underappreciated cause of dizziness on GLP-1 medications. Maintaining electrolyte levels (sodium, potassium, magnesium) through a nutrient-dense diet or targeted supplementation is also important, as these minerals are frequently depleted in GLP-1 users. Standing up slowly reduces postural hypotension episodes. If symptoms are severe or persistent, discuss them with your prescriber.

Does dizziness from GLP-1 medications go away?

Mild lightheadedness and dizziness in the early weeks of treatment often resolves as the body adapts. Positional vertigo caused by BPPV is very treatable with the Epley manoeuvre. However, the study shows vestibular disorder risk increases over years of GLP-1 use rather than peaking early, suggesting this is not purely a start-up side effect for all patients. Persistent or worsening dizziness warrants evaluation by an ear, nose, and throat specialist.